Current Liabilities
Other Commercial Liabilities
Johnson & Johnson Other Commercial Liabilities decreased by 13.9% to $7.40B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.5%, from $7.91B to $7.40B. Over 5 years (FY 2020 to FY 2025), Other Commercial Liabilities shows a downward trend with a -9.3% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ4 2008
Last reportedQ1 2026Apr 22, 2026
Metric ID:
commercial_liabilities_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $10.49B | $13.81B | $13.61B | $13.01B | $12.61B | $11.95B | $10.72B | $11.20B | $10.61B | $10.10B | $10.21B | $10.32B | $10.54B | $11.45B | $8.55B | $7.91B | $7.40B | $7.60B | $8.59B | $7.40B |
| QoQ Change | — | +31.7% | -1.4% | -4.5% | -3.1% | -5.2% | -10.3% | +4.5% | -5.3% | -4.8% | +1.1% | +1.1% | +2.1% | +8.6% | -25.3% | -7.4% | -6.4% | +2.7% | +13.1% | -13.9% |
| YoY Change | — | — | — | — | +20.2% | -13.5% | -21.3% | -13.9% | -15.9% | -15.5% | -4.7% | -7.9% | -0.6% | +13.4% | -16.3% | -23.3% | -29.7% | -33.6% | +0.5% | -6.5% |
Range$7.40B – $13.81B
CAGR-7.1%
Avg YoY Growth-10.5%
Median YoY Growth-13.7%
Other Commercial Liabilities at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's other commercial liabilities?
- Johnson & Johnson (JNJ) reported other commercial liabilities of $7.40B in Q1 2026.
- How has Johnson & Johnson's other commercial liabilities changed year-over-year?
- Johnson & Johnson's other commercial liabilities decreased by 6.5% year-over-year, from $7.91B to $7.40B.
- What is the long-term trend for Johnson & Johnson's other commercial liabilities?
- Over 5 years (2020 to 2025), Johnson & Johnson's other commercial liabilities has grown at a -9.3% compound annual growth rate (CAGR), from $13.97B to $8.59B.